

| | |
|---------|--|
| In vivo | expression of WNT7B in a time-dependent manner[1]. This study utilized the MDA-MB-453 xenograft tumor model in male SCID mice, demonstrating ARD-61's potent anti-tumor activity through daily intraperitoneal administration at specified dosages over a set period, resulting in effective tumor growth inhibition[1]. |
|---------|--|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|-----------|
| 1 mM | 0.9126 mL | 4.5629 mL | 9.1258 mL |
| 5 mM | 0.1825 mL | 0.9126 mL | 1.8252 mL |
| 10 mM | 0.0913 mL | 0.4563 mL | 0.9126 mL |
| 50 mM | 0.0183 mL | 0.0913 mL | 0.1825 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Lijie Zhao, et al. A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo. *Neoplasia*. 2020 Oct;22(10):522-532.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481